Advances in Diabetes Management: Tackling Polypharmacy, Assessing Prediabetes Cancer Risks, and Cellular Mechanisms of Fatty Liver

Journal of Diabetes Investigation: Vol. 14, Issue 10 Summary

This issue of the Journal of Diabetes Investigation highlights crucial clinical and basic science research aimed at improving safety, understanding broader health risks, and uncovering the biological mechanisms of diabetes-related complications.

Key research themes explored in this issue include:

• Medication Safety (Polypharmacy): Exploring how structured, multidisciplinary team interventions can safely reduce the burden of taking multiple medications (polypharmacy) in hospitalized diabetes patients.
• Systemic Risks of Prediabetes: Evaluating the potential link between prediabetes and increased risk of lung cancer incidence and mortality.
• Organ Crosstalk in Diabetes: Investigating how fat cells communicate with liver cells under high glucose conditions, accelerating fatty liver disease.

For patients and families, these findings underscore the clinical importance of comprehensive care—ranging from careful medication reviews to early lifestyle changes that address metabolic health before full-blown diabetes develops.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Clinical Safety & Medication Management

Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitus

Authors: Shohei Nishida, Takehiro Kato, Yuichi Hayashi, Shoya Yamada, Hironori Fujii, Michi Yamada, Nao Asai, Shinya Shimizu, Takashi Niwa, Hirotoshi Iihara, Sodai Kubota, Mayu Sakai, Yoshihiro Takahashi, Ken Takao, Masami Mizuno, Takuo Hirota, Ryo Kobayashi, Yukio Horikawa, Daisuke Yabe, Akio Suzuki

Research Objective:
To evaluate whether a structured program combining pharmacist checks with a multidisciplinary clinical team review can safely reduce the number of inappropriate medications (polypharmacy) in patients hospitalized for diabetes.

Methods:
This single-center, retrospective study included 102 patients with diabetes who were taking six or more medications upon admission to the Gifu University Hospital diabetes ward between July 2021 and June 2022. Pharmacists used a dedicated checklist to spot potentially inappropriate medications, which were then reviewed by a multidisciplinary clinical team for potential discontinuation. Medication numbers were compared between admission and discharge, and patients were monitored for any decline in health.

Main Findings:
Out of 308 admitted patients, 102 met the criteria for polypharmacy (taking 6+ drugs). Following the team's review, 84 inappropriate or potentially inappropriate medications were discontinued. The average number of medications per patient decreased significantly from 9.26 on admission to 8.42 at discharge. Follow-up monitoring confirmed that the reduction in medications did not cause any deterioration in the patients' health conditions.

Clinical Significance:
Polypharmacy increases the risk of side effects and drug interactions. This study shows that a collaborative review process involving pharmacists and doctors can safely and effectively trim down unnecessary drug prescriptions in diabetes patients.

Key Points for Patients:
If you are taking many different medications, it can sometimes lead to unnecessary side effects or confusion. A regular review of your medications by a clinical team can help safely reduce your pill burden without harming your health. Always consult your doctor before stopping any prescribed medication.

DOI: https://doi.org/10.1111/jdi.14046
Read the original article

Epidemiology & Prevention

Prediabetes and the risk of lung cancer incidence and mortality: A meta‐analysis

Authors: Enjian Shen, Xi Chen

Research Objective:
To investigate whether prediabetes (elevated blood sugar levels that are not yet high enough to be classified as type 2 diabetes) is associated with an increased risk of developing or dying from lung cancer.

Methods:
The researchers conducted a systematic review and meta-analysis of 10 observational cohort studies retrieved from major medical databases (including Medline, Embase, Cochrane Library, and Web of Science) to examine the relationship between prediabetes and lung cancer outcomes in adult populations.

Main Findings:
Individuals with prediabetes had a mildly increased risk of developing lung cancer compared to individuals with normal blood sugar levels (normoglycemia) (Risk Ratio: 1.09). This increased risk was notable in men, but not statistically significant in women. Additionally, the analysis suggested that prediabetes might be associated with a higher risk of lung cancer-related mortality.

Clinical Significance:
These findings highlight that metabolic impairment, even at the prediabetic stage, could have wider health implications beyond cardiovascular and metabolic risks, potentially influencing cancer risk and outcomes.

Key Points for Patients:
Prediabetes is a warning sign that blood sugar is higher than normal. Managing prediabetes through healthy lifestyle changes, such as balanced nutrition and regular physical activity, is vital not only to prevent type 2 diabetes but also to help lower the risk of other serious health issues, including certain types of cancer.

DOI: https://doi.org/10.1111/jdi.14057
Read the original article

Basic Science & Complications

LINC01705 derived from adipocyte exosomes regulates hepatocyte lipid accumulation via an miR‐552‐3p/LXR axis

Authors: Anhua Lin, Wenjing He

Research Objective:
To explore how high blood sugar levels prompt fat cells (adipocytes) to communicate with liver cells (hepatocytes), leading to fat buildup in the liver (fatty liver disease) in diabetic patients.

Methods:
Researchers isolated microscopic packages called "exosomes" released by human fat cells cultured under normal and high glucose conditions, as well as from patients with diabetes and those with diabetes complicated by fatty liver disease. They introduced these exosomes to laboratory-grown liver cells (HepG2) and measured fat accumulation and genetic activity within the liver cells.

Main Findings:
High glucose levels caused fat cells to release exosomes rich in a specific genetic molecule called LINC01705. Exosomes from patients with both diabetes and fatty liver disease showed the highest levels of LINC01705. When liver cells absorbed these exosomes, LINC01705 suppressed a protective molecule (miR-552-3p), triggering liver fat accumulation via the LXR pathway.

Clinical Significance:
This study reveals a new pathway of "cellular communication" between fat tissue and the liver under high glucose conditions, showing how poorly controlled blood sugar can directly promote fatty liver disease.

Key Points for Patients:
This basic scientific study helps us understand why having high blood sugar makes you more likely to develop a fatty liver. It shows that fat cells in the body can send chemical packages that cause liver cells to store unnecessary fat, emphasizing the importance of keeping blood sugar levels under control to protect your liver health.

DOI: https://doi.org/10.1111/jdi.14050
Read the original article

Understanding Diabetic Complications: New Research on Fatty Liver Biomarkers, Prediabetes Organ Damage, and Kidney Disease Progression

Journal of Diabetes Investigation: Volume 13, Issue 5 Summary

In this monthly review, we explore critical advancements in understanding how diabetes and metabolic disorders impact multiple organs. The research in this issue highlights three main areas:

• Early Biomarkers for Fatty Liver: Identifying specific proteins in the blood, such as FABP4, that can help predict the onset of metabolic dysfunction-associated fatty liver disease (MAFLD) in older adults.
• The Hidden Damages of Prediabetes: Revealing how high-sugar and high-fat diets trigger systemic stress and tissue damage in vital organs long before full-blown type 2 diabetes develops.
• Immune-Driven Kidney Damage: Discovering how specific proteins of our body's immune system (the complement system) can build up in the kidneys, accelerating the progression toward kidney failure in patients with diabetic nephropathy.

For patients and families, these studies underscore the vital importance of early detection, lifestyle interventions, and targeted medical monitoring to prevent long-term complications affecting the liver, kidneys, and heart.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Biomarkers & Fatty Liver

Circulating Fatty Acid-Binding Protein 4 (FABP4) as a Predictor of Fatty Liver Disease in Older Adults

Authors: Marenao Tanaka, Satoko Takahashi, Yukimura Higashiura, Akiko Sakai, Masayuki Koyama, Shigeyuki Saitoh, Kazuaki Shimamoto, Hirofumi Ohnishi, Masato Furuhashi

Research Objective

The researchers aimed to understand the relationship between a protein called FABP4 (fatty acid-binding protein 4) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in middle-aged and elderly individuals. MAFLD is a chronic liver disease defined by fat buildup in the liver combined with type 2 diabetes, being overweight, or having other metabolic dysregulations.

Methods

The study evaluated 627 participants (292 men and 335 women) with a mean age of 65 years from the Tanno-Sobetsu Study. The team measured metabolic markers in the blood—including FABP4, fibroblast growth factor 21, and adiponectin. They used the "Fatty Liver Index" (FLI), a calculated score incorporating body measurements and blood markers, to detect fat accumulation in the liver.

Main Findings

The researchers found that higher Fatty Liver Index scores correlated with elevated blood pressure, insulin resistance, and increased levels of FABP4. Even after adjusting for other variables like age, biological sex, diabetes, high blood pressure, and cholesterol levels, the concentration of FABP4 in the blood remained an independent predictor of fatty liver disease.

Clinical Significance

FABP4 is primarily produced by fat cells and is known to be involved in the development of insulin resistance and hardened arteries. This study demonstrates that tracking FABP4 levels in the blood could serve as a valuable diagnostic tool to identify patients at higher risk of developing metabolic-related fatty liver disease.

Key Points for Patients

Fatty liver disease is closely tied to overall metabolic health. If you are middle-aged or older, managing your metabolic health can protect your liver. In the future, doctors may use blood tests like FABP4 to detect early signs of fatty liver, allowing you to make proactive changes before serious liver damage occurs.

DOI: https://doi.org/10.1111/jdi.13735
Read the original article →

Diet & Prediabetes Impact

How a Prediabetic Diet Triggers Hidden Tissue and Hormone Damage Across Vital Organs

Authors: Bongeka Cassandra Mkhize, Palesa Mosili, Phikelelani Sethu Ngubane, Ntethelelo Hopewell Sibiya, Andile Khathi

Research Objective

While full-blown type 2 diabetes is strongly linked to organ damage and hormone imbalances, the impacts of moderate high blood sugar (prediabetes) are less understood. This laboratory study investigated how diet-induced prediabetes affects the renin-angiotensin-aldosterone system (RAAS)—a hormone pathway that regulates blood pressure and fluid balance—in various organs.

Methods

Male laboratory rats were divided into two groups: one was fed a standard healthy diet, and the other was fed a high-fat, high-carbohydrate diet for 32 weeks to induce a prediabetic state. The researchers then analyzed RAAS hormone activity, levels of stress-inducing molecules (oxidative stress), and protective antioxidants within the animals' skeletal muscles, fat tissues, livers, pancreases, and hearts.

Main Findings

In the diet-induced prediabetes group, multiple RAAS hormone components were elevated across almost all selected organs. This hormone elevation was accompanied by an increase in oxidative stress (harmful cellular waste molecules) and a sharp decrease in the organs' natural protective antioxidants. Additionally, the prediabetic rats showed high accumulations of fat (triglycerides) in their livers.

Clinical Significance

These findings show that even before a person develops full diabetes, a poor diet can trigger local tissue stress and over-activate hormone systems in crucial organs. This underlying stress likely acts as a major driver for the cardiovascular, liver, and pancreatic complications commonly seen in metabolic conditions.

Key Points for Patients

Prediabetes is not just a "warning sign"; it is a state where organs can already experience silent strain. Eating a diet high in fats and refined sugars can disturb your body's hormone levels and cause cellular stress in your heart, liver, and muscles. Catching and managing prediabetes early through healthy eating and active living is key to protecting your organs.

DOI: https://doi.org/10.1111/jdi.13690
Read the original article →

Kidney Complications

Complement Immune System Activation May Accelerate Diabetic Kidney Disease Progression

Authors: Yuanyuan Jiao, Shimin Jiang, Ying Wang, Tianyu Yu, Guming Zou, Li Zhuo, Wenge Li

Research Objective

Diabetic nephropathy is a serious kidney disease caused by diabetes. The researchers set out to determine whether the complement system—a key part of our body's immune system designed to clear pathogens—plays a role in damaging the filtering units of the kidney (the glomeruli) and accelerating kidney failure.

Methods

The research team combined genomic analysis with actual physical examinations of kidney tissues (histopathology). They analyzed gene expression datasets from public databases to identify key "hub" genes. Then, they evaluated kidney tissue biopsies from patients with diabetic nephropathy to look for deposits of complement proteins (specifically C1q and C3) and followed their clinical progress over time.

Main Findings

Genetic screening highlighted three complement-related genes (C3, C1QB, and C1QA) at the center of diabetic kidney changes. When examining biopsy samples under the microscope, patients who had physical deposits of both C1q and C3 in their kidney filters had far more severe tissue damage. Crucially, these patients were found to be at a significantly higher risk of experiencing complete kidney failure.

Clinical Significance

This research provides solid clinical and genetic evidence that an overactive immune response (specifically the classical complement pathway) is directly involved in worsening diabetic kidney damage. Identifying these immune deposits can act as an important risk predictor for kidney failure.

Key Points for Patients

In some people, diabetes triggers an over-activation of the immune system inside the kidneys, which acts like "friendly fire" damaging healthy tissue. If doctors identify these immune proteins in kidney tests, it helps them recognize patients who need more intensive treatment. This discovery also paves the way for future medical therapies designed to block this immune pathway and protect the kidneys.

DOI: https://doi.org/10.1111/jdi.13739
Read the original article →

Advances in Diabetes Care: Key Insights from the Journal of Diabetes Investigation (Vol. 13, Issue 3)

Journal of Diabetes Investigation: Vol. 13, Issue 3 Review

In this issue of the Journal of Diabetes Investigation, clinical researchers explore several critical facets of diabetes management, complications, and early risk assessment. Key investigations focus on the metabolic impacts of clinical dropout, the synergistic dangers of combined vision and hearing impairments on cardiovascular outcomes, and nuanced screening metrics for prediabetes.

Key Takeaways for Patients and Families: Continuous clinical oversight remains the cornerstone of safe diabetes management. Gaps in care can trigger severe blood sugar spikes, particularly for patients prescribed insulin or sulfonylureas. Furthermore, sensory health assessments (vision and hearing) are shown to be essential indicators of overall cardiovascular risk, and early-stage screening tools like the Visceral Adiposity Index (VAI) or combined ankle-brachial index sweat tests are making preventative interventions more precise than ever.

Disclaimer
The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Continuity of Care

Glycemic Deterioration After Dropping Out of Type 2 Diabetes Care

Research Objective: To identify factors associated with worsening blood sugar control (HbA1c) when patients with type 2 diabetes temporarily stop receiving clinical care.

Methods: A retrospective cohort study analyzed medical claims and health checkup data of 1,125 Japanese workers with type 2 diabetes who had paused their clinical care for at least 4 months after receiving continuous care for over 1.5 years.

Main Findings: Following an average dropout period of 9.3 months, the average HbA1c level rose from 6.8% to 7.6%. Patients who were taking insulin or sulfonylureas before their dropout experienced a severe increase in HbA1c of approximately 2% or more, even if their blood sugar had been well-controlled prior to the gap in treatment. Patients not on medication experienced far smaller increases (+0.5%).

Clinical Significance: A temporary halt in care poses a high risk for rapid metabolic deterioration, especially for those dependent on advanced glucose-lowering drugs.

What this means for you: Skipping your diabetes clinic appointments is dangerous, particularly if you are prescribed insulin or sulfonylureas. Even if your blood sugar feels controlled, stopping therapy without supervision can lead to rapid and severe health setbacks.

DOI: https://doi.org/10.1111/jdi.13681
Read the original article

Sensory Complications & Cardiovascular Risk

Impact of Vision and Hearing Impairments on Cardiovascular Health in Type 2 Diabetes

Research Objective: To examine how vision loss, hearing loss, or a combination of both relates to cardiovascular disease risk and overall mortality in individuals with type 2 diabetes.

Methods: A large nationwide cohort study evaluated 771,128 patients with type 2 diabetes in South Korea, comparing rates of myocardial infarction (MI), stroke, and mortality among those with and without sensory impairments.

Main Findings: Patients with sensory deficits exhibited elevated risk profiles. Those suffering from both vision and hearing impairments had the highest vulnerability, presenting an adjusted hazard ratio of 1.362 for MI and 1.591 for mortality. Vision loss alone was linked to a higher risk of adverse cardiovascular outcomes and mortality than hearing loss alone.

Clinical Significance: Vision and hearing impairments serve as potent independent and synergistic markers for severe cardiovascular events and overall mortality in diabetes patients.

What this means for you: Routine eye and ear examinations do more than protect your senses; they are vital windows into your heart and vascular system. If you notice deterioration in your sight or hearing, discuss cardiovascular screening with your doctor.

DOI: https://doi.org/10.1111/jdi.13689
Read the original article

Early Diagnostics

Fasting Plasma Glucose of 90–99 mg/dL and Type 2 Diabetes Risk

Research Objective: To clarify whether a fasting blood sugar level between 90 and 99 mg/dL—traditionally considered "normal"—increases the risk of developing type 2 diabetes.

Methods: This long-term retrospective cohort study tracked 37,148 Japanese individuals with normal baseline blood glucose over a 10-year period (2008 to 2018).

Main Findings: Within the 90–99 mg/dL range, the risk of developing type 2 diabetes rose by 9% for every 1 mg/dL increase. Compared to individuals with fasting glucose ≤89 mg/dL, those at 98–99 mg/dL had over a 3.4-fold higher risk of developing diabetes, with the hazard ratio remaining highly pronounced among individuals with obesity.

Clinical Significance: The risk of progressing to type 2 diabetes increases linearly and significantly even within what is widely considered a normal fasting blood sugar range.

What this means for you: Having a fasting blood sugar level in the high 90s is not entirely risk-free. It serves as an early warning, particularly if you are carrying extra weight, indicating that proactive lifestyle modifications could prevent diabetes.

DOI: https://doi.org/10.1111/jdi.13692
Read the original article

Retinopathy Mechanisms

LncRNA ATP2B1-AS1 Regulates Blood Vessel Leakage in Diabetic Retinopathy

Research Objective: To investigate how the long non-coding RNA (lncRNA) ATP2B1-AS1 influences biological abnormalities in retinal cells exposed to high sugar levels.

Methods: A laboratory-based molecular study evaluating human retinal endothelial cells (HRECs) under high-glucose conditions mimicking diabetes.

Main Findings: ATP2B1-AS1 was found to be downregulated in diabetic retinopathy. Artificially restoring (overexpressing) its levels significantly reduced cell growth, cellular migration, unwanted new blood vessel growth (angiogenesis), and vessel leakiness (permeability) induced by high glucose. This protective effect occurred because ATP2B1-AS1 acts as a "sponge" for miR-4729, which in turn regulates the IQGAP2 gene.

Clinical Significance: This study maps out a new genetic protective pathway in retinal cells, opening the door for future targeted genetic therapies to prevent vision loss.

What this means for you: Researchers are pinpointing the exact genetic mechanisms behind eye damage caused by diabetes. Discoveries like this help pave the way for highly targeted medications in the future to stop retinopathy before it damages sight.

DOI: https://doi.org/10.1111/jdi.13740
Read the original article

Prediabetes Biomarkers

Visceral Adiposity Index as an Indicator for Prediabetes Risk

Research Objective: To synthesize existing observational evidence to clarify whether the Visceral Adiposity Index (VAI)—a combined measure of fat distribution and lipid levels—is associated with prediabetes risk.

Methods: A systematic meta-analysis combining data from 10 observational studies involving a total of 112,603 participants.

Main Findings: Higher VAI scores were significantly associated with an elevated risk of prediabetes. The overall combined odds ratio of VAI for prediabetes was 1.68, although there was notable heterogeneity and publication bias across the studied pools.

Clinical Significance: VAI serves as a useful lipid-and-body-measurement index that clinicians can use to flag individuals who are highly likely to develop prediabetes.

What this means for you: Evaluating your risk for prediabetes involves more than just a scale. By looking at a combined picture of your body fat distribution and cholesterol panel, doctors can better understand your risk and help you take preventative action early.

DOI: https://doi.org/10.1111/jdi.13685
Read the original article

Insulin & Therapy Innovation

Simplified Combination Therapy vs. Multiple Daily Injections in Japanese Type 2 Patients

Research Objective: To compare the clinical efficacy, safety, and blood sugar stability of a simplified once-daily combined injection (iGlarLixi + insulin glulisine) against a traditional intensive multiple daily injection (MDI) regimen.

Methods: A randomized trial involving 40 hospitalized Japanese type 2 diabetes patients, monitored with intermittent continuous glucose monitoring (iCGM) to adjust doses and track glucose metrics.

Main Findings: Both therapies offered comparable "time in range" (healthy blood sugar window). However, the combined iGlarLixi + glulisine therapy significantly reduced time spent in hypoglycemia (low blood sugar), required a shorter medication adjustment (titration) period, and simplified the overall treatment process.

Clinical Significance: Transitioning to a simplified combined therapy maintains strong blood sugar control while offering a safer profile with fewer daily injections and lower hypoglycemia risks.

What this means for you: Managing diabetes does not always have to mean taking numerous complex shots. Combined formulas can provide equivalent glycemic control with fewer needle sticks and a lower danger of sudden, scary low blood sugar events.

DOI: https://doi.org/10.1111/jdi.13677
Read the original article

Therapeutic Molecules

Effects of EPA on Selenoprotein P and Organ-Specific Insulin Sensitivity

Research Objective: To investigate if taking eicosapentaenoic acid (EPA)—a polyunsaturated fatty acid—reduces circulating levels of Selenoprotein P (SeP, a protein that induces insulin resistance) and improves organ-specific insulin response in humans.

Methods: 20 participants with dyslipidemia and type 2 diabetes were randomized to receive 900 mg of EPA twice daily or control for 12 weeks. Detailed insulin sensitivity tests (hyperinsulinemic-euglycemic clamp with stable isotope tracer) were conducted.

Main Findings: Overall circulating SeP levels did not decrease in either group. However, EPA treatment significantly improved insulin sensitivity in fat (adipose) tissue. In individual correlations, higher EPA levels were positively associated with improved hepatic (liver) insulin sensitivity, though surprisingly showing a negative association in skeletal muscle.

Clinical Significance: EPA's ability to bolster insulin response in the liver and fat tissues appears to work through complex, tissue-specific mechanisms independent of circulating SeP levels.

What this means for you: High-quality EPA (often derived from fish oil) can help improve how your body fat and liver respond to insulin. However, its metabolic actions are complex, so it should be used in coordination with your standard medical therapies.

DOI: https://doi.org/10.1111/jdi.13697
Read the original article

Circulatory Screening

Combining Ankle-Brachial Index and Foot Sweat Conductance for Early Leg Artery Disease

Research Objective: To evaluate the early diagnostic value of combining the ankle-brachial index (ABI) with feet electrochemical skin conductance (FESC, measuring sweat response) to detect peripheral artery disease (PAD) in Chinese type 2 diabetes patients.

Methods: Evaluated 183 type 2 diabetes patients who were classified into three groups: uncomplicated diabetes, patients with nerve damage (neuropathy), and patients with established PAD.

Main Findings: FESC (measured via a rapid Sudoscan test) was identified as an independent risk factor for developing PAD. Combining the standard ankle-brachial blood pressure index with FESC produced excellent diagnostic results, achieving an accuracy area under the curve (AUC) of 0.907, with 91.4% specificity and 75% sensitivity.

Clinical Significance: Combining vascular (ABI) and sweat gland nerve (FESC) screenings provides an accurate, non-invasive method for detecting diabetes-related leg artery blockages at a very early stage.

What this means for you: Simple, non-invasive skin tests on your feet combined with blood pressure checks on your limbs can detect early signs of poor circulation. Catching these problems early is the key to preventing serious diabetic foot ulcers.

DOI: https://doi.org/10.1111/jdi.13687
Read the original article

Advances in Diabetes Research: Dietary Fats, Early Detection, and Safe Treatments

Journal of Diabetes Investigation (Vol. 11, Issue 2) Monthly Review

This issue brings together crucial clinical insights spanning the entire spectrum of diabetes care, from molecular mechanisms to practical lifestyle choices and treatment safety profiles. Key research themes highlighted in this review include:

• Early Complication Signals: Discovering how subtle nerve performance changes can be detected even during the prediabetic stage, allowing for earlier protective interventions.
• Dietary and Hormonal Balance: Exploring how specific healthy fats (omega-3s) are linked to lower inflammatory markers, and how appetite-related hormones fluctuate in type 2 diabetes.
• Safe & Effective Management: Evaluating the security of modern diabetes medications for older adults and identifying hidden risk links between breast cancer and subsequent diabetes onset.

Understanding these advancements empowers patients and families to engage in more proactive, informed discussions with their healthcare teams regarding prevention, nutrition, and personalized treatment plans.

Disclaimer The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Pancreatic Health

Wingless-type MMTV integration site family member 5a is a key inhibitor of islet stellate cells activation

Authors: Wei Xu, HouFa Geng, Jun Liang, Ying Liu, Qian Lv, Jie Wang, Rui Li, Xiu Li Wang, Xui Kui Liu, Peter M Jones, Zi Lin Sun

Research Objective:
To explore how a specific protein pathway called Wnt5a influences islet stellate cells (ISCs) in the pancreas, which are known to contribute to insulin-producing cell dysfunction when abnormally activated in type 2 diabetes.

Methods:
The researchers isolated islet stellate cells from diabetic mice (db/db) and non-diabetic mice (db/m). They analyzed the expression levels of the Wnt5a protein and used lab-based molecular interventions to increase or block its activity, monitoring cell migration, growth, and structural changes.

Main Findings:
The study showed that diabetic mice had significantly lower levels of Wnt5a. Restoring or overexpressing Wnt5a stopped these pancreatic cells from activating and spreading. This protective effect occurred by shutting down a cellular signal chain (the Smad2/3 pathway) through a specific receptor (frizzled-5).

Clinical Significance:
By keeping islet stellate cells "quiet" or inactive, Wnt5a helps protect the insulin-producing beta cells of the pancreas. This opens up potential new avenues for therapies designed to maintain healthy pancreatic function in individuals with type 2 diabetes.

Key Points for Patients:
Our pancreas contains specialized cells that, when stressed or hyperactive, can impair our ability to produce insulin. Researchers have identified a natural molecular "brake" (Wnt5a) that stops this harmful cellular hyperactivity, paving the way for future protective diabetes drugs.

Original Article Link:
Read the original article (DOI: 10.1111/jdi.13124)

Kidney Disease Biomarkers

Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease

Authors: Tomohito Gohda, Nozomu Kamei, Takeo Koshida, Mitsunobu Kubota, Kanako Tanaka, Yoshinori Yamashita, Eri Adachi, Saki Ichikawa, Maki Murakoshi, Seiji Ueda, Yusuke Suzuki

Research Objective:
To evaluate the relevance of Kidney Injury Molecule-1 (KIM-1) levels in the blood (serum) versus the urine as a tool for tracking kidney function changes in patients living with type 2 diabetes.

Methods:
Blood and urine samples were evaluated in 602 patients diagnosed with type 2 diabetes who had a mild-to-moderate baseline kidney clearance rate (estimated glomerular filtration rate, or eGFR, of 30 mL/min/1.73 m² or higher). The researchers grouped participants by their eGFR levels to see which KIM-1 test correlated best with declining kidney function.

Main Findings:
While both serum and urine levels varied among the groups, KIM-1 levels in the blood (serum) were much more strongly associated with key indicators of kidney function (such as eGFR) than levels measured in the urine.

Clinical Significance:
This suggests that measuring KIM-1 through a standard blood test rather than a urine test may offer doctors a more reliable biomarker for monitoring and managing diabetic kidney disease in everyday clinical practice.

Key Points for Patients:
Protecting kidney health is a top priority in diabetes care. This study shows that a simple blood test measuring a protein called KIM-1 could help doctors detect and track kidney changes more reliably than urine tests alone.

Original Article Link:
Read the original article (DOI: 10.1111/jdi.13139)

Genetics & Young-Onset Diabetes

Identification of a compound heterozygous inactivating ABCC8 gene mutation responsible for young-onset diabetes with exome sequencing

Authors: Norihiko Matsutani, Hiroto Furuta, Shohei Matsuno, Yoshimasa Oku, Shuhei Morita, Shinsuke Uraki, Asako Doi, Machi Furuta, Hiroshi Iwakura, Hiroyuki Ariyasu, Masahiro Nishi, Takashi Akamizu

Research Objective:
To identify the genetic driver of diabetes in two young brothers who developed the condition during their late teens (ages 15 and 18).

Methods:
The researchers performed whole-exome sequencing (a detailed analysis of all the protein-coding genes in the DNA) on the brothers and their parents.

Main Findings:
They discovered that both brothers carried a "compound heterozygous" mutation (two different mutations on the same gene, one inherited from each parent) in the ABCC8 gene. While each parent carried only one of these mutations and did not have diabetes, the combination of both mutated copies caused the gene to become inactive, leading to diabetes in the brothers.

Clinical Significance:
Mutations in the ABCC8 gene are typically known for causing low blood sugar (hypoglycemia) in infancy. This study demonstrates that these same inactivating mutations can also lead to the development of diabetes later in youth, clarifying how genetic variations dictate different forms of diabetes.

Key Points for Patients:
When diabetes develops unusually early in life, genetics can play a major role. Advanced genetic sequencing helps families understand the root cause of their condition and can guide doctors toward highly tailored treatment decisions.

Original Article Link:
Read the original article (DOI: 10.1111/jdi.13138)

Nutrition & Heart Health

Ratios of serum eicosapentaenoic acid to arachidonic acid and docosahexaenoic acid to arachidonic acid were inversely associated with serum resistin levels: The Hisayama Study

Authors: Mayu Higashioka, Yoichiro Hirakawa, Ryoichi Kawamura, Takanori Honda, Jun Hata, Daigo Yoshida, Yasunori Takata, Takanari Kitazono, Haruhiko Osawa, Toshiharu Ninomiya

Research Objective:
To investigate whether the ratio of beneficial n-3 fatty acids (EPA and DHA, commonly found in fish oil) to n-6 fatty acids (arachidonic acid) in the blood is linked to blood levels of resistin, an inflammatory protein that contributes to insulin resistance and clogged arteries.

Methods:
This large-scale study analyzed blood markers from 3,200 Japanese residents aged 40 and older, adjusting for age, sex, and other health variables.

Main Findings:
People with higher ratios of EPA and DHA compared to arachidonic acid had significantly lower levels of inflammatory resistin in their blood. This relationship remained solid even after adjusting for lifestyle factors and body weight.

Clinical Significance:
The findings highlight a clear physiological link between consuming omega-3 polyunsaturated fatty acids and lower systemic inflammation. Increasing n-3 levels through diet or supplementation may help mitigate insulin resistance and cardiovascular risks.

Key Points for Patients:
Choosing foods rich in healthy omega-3 fatty acids, such as salmon, mackerel, and other seafood, can help lower inflammatory proteins in your body. This diet adjustment helps protect against insulin resistance and supports long-term heart health.

Original Article Link:
Read the original article (DOI: 10.1111/jdi.13129)

Co-occurring Conditions

Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer

Authors: Chih-Yuan Wang, Shyang-Rong Shih, Kuo-Chin Huang

Research Objective:
To determine whether postmenopausal women diagnosed with primary breast cancer face an increased risk of developing type 2 diabetes over time.

Methods:
Using database records from Taiwan, the researchers tracked 4,607 postmenopausal women (aged 55+) with breast cancer and compared them to 23,035 age-matched women without breast cancer over a 15-year period.

Main Findings:
Women with breast cancer had a significantly higher risk of developing diabetes. This risk was highest in the first year after diagnosis (1.7-fold higher) and remained elevated throughout the 15-year follow-up period. This trend persisted regardless of whether they received hormone therapy.

Clinical Significance:
Postmenopausal women undergoing breast cancer management require systematic, routine screening for blood sugar changes so that diabetes can be identified early, reducing complications and improving overall recovery outcomes.

Key Points for Patients:
If you or a loved one is a postmenopausal woman navigating breast cancer treatment, it is important to include regular blood sugar monitoring as part of your ongoing health plan. Early detection of blood sugar changes makes diabetes much easier to manage.

Original Article Link:
Read the original article (DOI: 10.1111/jdi.13112)

Nerve Health

Early sensory neurophysiological changes in prediabetes

Authors: Yi-Chen Lin, Cindy Shin-Yi Lin, Tsui-San Chang, Jing-Er Lee, Jowy Tani, Hung-Ju Chen, Jia-Ying Sung

Research Objective:
To investigate whether nerve changes begin as early as prediabetes (borderline blood sugars) and to identify early diagnostic markers for nerve issues before symptoms appear.

Methods:
Nerve excitability tests were conducted across three groups of participants: individuals with normal blood sugar, individuals with prediabetes, and individuals with diabetes.

Main Findings:
The researchers found that a phenomenon called nerve "superexcitability" (hyper-reactivity in the nerve recovery cycle) and delayed signal speeds in the hands (median nerve) worsened progressively from normal to prediabetes, and then to diabetes. This superexcitability directly correlated with higher HbA1c and fasting blood sugar levels.

Clinical Significance:
These results confirm that nerve degradation begins well before a formal diagnosis of type 2 diabetes. Routine physiological nerve screening could help identify patients at risk of neuropathy during the prediabetic phase, when progression can still be managed or reversed.

Key Points for Patients:
Even slightly elevated blood sugars (prediabetes) can start affecting our nerves. Living an active lifestyle and eating a healthy diet to manage prediabetes can protect your hands and feet from long-term nerve damage and numbness.

Original Article Link:
Read the original article (DOI: 10.1111/jdi.13148)

Therapeutics & Geriatric Care

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study)

Authors: Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya

Research Objective:
To evaluate the safety and clinical effectiveness of the SGLT2 inhibitor tofogliflozin in real-world elderly Japanese patients (aged 65 and older) with type 2 diabetes, based on the number of other diabetes medications they were already taking.

Methods:
This 1-year prospective study analyzed clinical outcomes for 1,497 elderly patients who started tofogliflozin. Researchers evaluated safety events (including dehydration and low blood sugar) across groups taking zero, one, two, or three-plus other diabetes medications, or insulin.

Main Findings:
Tofogliflozin effectively reduced HbA1c levels and body weight without negatively affecting kidney function. Mild side effects like volume depletion (dehydration) occurred occasionally, but low blood sugar (hypoglycemia) was rare (1.07%), showing consistent safety and benefit regardless of other background diabetes drugs.

Clinical Significance:
This study provides reassuring real-world evidence that tofogliflozin can be safely and successfully used by older adults, simplifying treatment plans and aiding weight management without excessive risk of dangerous low blood sugars.

Key Points for Patients:
For older individuals, finding safe diabetes therapies that do not cause sudden drops in blood sugar is incredibly important. This study shows that tofogliflozin is a reliable, supportive option for older adults, even if they are already taking other diabetes medications.

Original Article Link:
Read the original article (DOI: 10.1111/jdi.13125)

Key Diabetes Research: Exploring Testosterone, Prediabetes Risk, Eye Health, and New Management Approaches

Issue Summary (JDI Vol.6, Issue4)

This issue of the Journal of Diabetes Investigation explores a diverse range of topics crucial for understanding and managing diabetes, from potential benefits of common medications to novel risk factors and improved patient support strategies. Key themes include the unexpected effects of initial diabetes treatments, early indicators of prediabetes, the often-overlooked role of specific eye cells in diabetic complications, and how early life factors can influence diabetes risk.

Notable studies include a pilot investigation suggesting that a common diabetes medication, sulfonylurea (glimepiride), might help restore testosterone levels in middle-aged men with type 2 diabetes. Another significant meta-analysis strengthens the link between lower levels of a beneficial hormone, adiponectin, and the presence of prediabetes, indicating its potential as an early warning sign. Researchers also shed light on the photoreceptors in the eye, proposing they play a critical, previously underestimated, role in diabetic retinopathy, opening new avenues for research into protecting vision.

For patients and families, this issue highlights several key points: Initial diabetes treatments may have broader benefits beyond blood sugar control; understanding your prediabetes risk factors, including hormone levels, is vital; protecting eye health involves more than just blood vessel care; and even factors like birthweight can impact your risk of developing diabetes later in life. Furthermore, a study on peer education shows its significant positive impact on the emotional well-being and self-management skills of type 2 diabetes patients, emphasizing the value of community support. Another study demonstrates how combining an injectable medication (liraglutide) with insulin therapy can stabilize blood sugar levels after meals, leading to more consistent control.

Collectively, these papers contribute to a more comprehensive understanding of diabetes, its complications, and effective management strategies, emphasizing personalized care and the importance of addressing both physical and psychological aspects of the condition.

Disclaimer

The information presented in this article is provided for informational purposes only. The blog and its author assume no responsibility for the accuracy, safety, completeness, or reliability of the information. Any actions or decisions based on the information in this article are the sole responsibility of the reader.

This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.

Individual Paper Reviews

Effects of sulfonylurea as initial treatment on testosterone of middle‐aged men with type 2 diabetes: A 16‐week, pilot study

Authors: Long Wong, Hong‐Mei Chen, Shui‐Qing Lai, Hua‐Zhang Yang, Jian Kuang, Jian‐Hao Pei

Research Objective

This pilot study aimed to investigate whether glimepiride, a type of sulfonylurea medication often used to treat type 2 diabetes, could affect testosterone levels in middle-aged men with the condition.

Methods

Researchers enrolled 15 middle-aged men with type 2 diabetes into this 16-week study. They were initially given 1 mg/day of glimepiride, with the dose adjusted based on their blood glucose levels. For comparison, another 15 healthy men of similar age and body mass index (BMI) were included as a control group.

Main Findings

• Compared to healthy controls, men with type 2 diabetes initially had significantly lower total testosterone levels and a reduced testosterone secretion index (a measure of how well the body produces testosterone).
• After 16 weeks of glimepiride treatment, blood glucose and lipid (fat) levels significantly improved in the diabetes group.
• Importantly, total testosterone levels significantly increased, and the testosterone secretion index values were significantly higher than at the start of the study.
• There were no significant changes in body weight, waist circumference, or levels of other related hormones like luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex hormone-binding globulin (SHBG).

Clinical Significance

This pilot study suggests that glimepiride, when used as an initial treatment for type 2 diabetes, might not only help control blood sugar but also recover decreased total testosterone levels and improve testosterone production in middle-aged men. This finding opens a new area of consideration for the broader benefits of sulfonylurea medications.

Key Points for Patients

If you are a middle-aged man with type 2 diabetes and low testosterone, taking a medication like glimepiride for your diabetes might also help improve your testosterone levels. Low testosterone can affect energy, mood, and other aspects of health, so this potential side benefit is worth discussing with your doctor. Always remember that this was a small pilot study, and more research is needed.

DOI: Read the original article

Association between the level of circulating adiponectin and prediabetes: A meta‐analysis

Authors: Huasheng Lai, Nie Lin, Zhenzhen Xing, Huanhuan Weng, Hua Zhang

Research Objective

This study aimed to determine if there is a consistent difference in circulating adiponectin levels between individuals with prediabetes and healthy controls by conducting a meta-analysis, which combines results from multiple studies.

Methods

The researchers performed a systematic search of medical literature databases (like PubMed and EMBASE) for studies that measured adiponectin levels in people with prediabetes and healthy individuals. They then pooled the data from 3 cohort studies and 15 case-control studies, involving a total of 41,841 participants, to statistically analyze the differences.

Main Findings

• Circulating adiponectin levels in people with prediabetes were significantly lower than in healthy controls (weighted mean difference of -1.694 μg/mL; 95% confidence interval -2.151 to -1.237; P < 0.001).
• Subgroup analyses showed even more significant differences in adiponectin levels in individuals with higher insulin resistance (measured by HOMA-IR > 2.12) and in older individuals (average age > 60 years).
• The differences in adiponectin levels also showed a trend related to body mass index (BMI) and age.

Clinical Significance

This meta-analysis provides strong evidence that adiponectin levels are lower in individuals with prediabetes compared to healthy individuals, suggesting that adiponectin decreases even before the full onset of diabetes. Adiponectin is a hormone that helps improve insulin sensitivity, so lower levels could indicate increased risk for developing type 2 diabetes. This finding supports its potential as a biomarker for early identification of prediabetes, especially in older adults and those with higher insulin resistance.

Key Points for Patients

Adiponectin is a beneficial hormone that helps your body use insulin more effectively. This large study suggests that if you have prediabetes, your adiponectin levels are likely lower than someone who is healthy. This might mean that a lower level of this hormone could be an early indicator of your risk for developing full-blown diabetes, particularly if you are older or have signs of insulin resistance. Further research might show if monitoring adiponectin could help identify those who need early interventions.

DOI: Read the original article

Photoreceptors in diabetic retinopathy

Authors: Timothy S Kern, Bruce A Berkowitz

Research Objective

This review article aimed to summarize recent findings suggesting that photoreceptors – the light-sensing cells in the eye – might play a crucial, but often overlooked, role in the development of diabetic retinopathy.

Methods

This was a review article, meaning it summarized and analyzed existing research and literature on the topic.

Main Findings

• Photoreceptors, despite making up a large portion of the retina and having high metabolic activity, have largely been ignored in the study of diabetic retinopathy (DR).
• Recent studies indicate that these photoreceptors might be critically involved in the diabetes-induced damage to the tiny blood vessels (capillaries) in the retina.
• The review highlights various changes in the structure and function of photoreceptors that occur due to diabetes.

Clinical Significance

This review challenges the traditional view of diabetic retinopathy, which primarily focuses on blood vessel damage. By highlighting the potential role of photoreceptors, it suggests a new perspective for understanding the pathogenesis (how the disease develops) of DR. This could lead to new research directions and, eventually, new strategies for diagnosing, preventing, or treating vision loss in people with diabetes by targeting these light-sensing cells directly.

Key Points for Patients

Diabetic retinopathy is a serious eye complication of diabetes. While we often hear about how diabetes damages blood vessels in the eye, this review points out that the cells responsible for detecting light (photoreceptors) might also be very important in how this damage develops. Understanding their role could eventually lead to new ways to protect your vision if you have diabetes. Regular eye exams remain crucial for early detection and management.

DOI: Read the original article

Association of birthweight with diabetes and insulin sensitivity or secretion in the Japanese general population

Authors: Junko Oya, Tomoko Nakagami, Moritoshi Kurita, Yayoi Yamamoto, Yukiko Hasegawa, Yuki Tanaka, Yasuhiro Endo, Yasuko Uchigata

Research Objective

This study aimed to investigate the relationship between birthweight and the risk of diabetes, as well as insulin resistance and insulin secretion, in the general adult population of Japan.

Methods

The study included 847 Japanese adults who underwent health check-ups. Participants were categorized into four groups based on their birthweight (low birthweight, defined as less than 2,500g, and three tertiles for those above 2,500g). Researchers used statistical models to assess the association between birthweight and diabetes prevalence, as well as measures of insulin resistance (HOMA-IR) and β-cell function (HOMA-β).

Main Findings

• The prevalence of diabetes tended to increase as birthweight decreased.
• Individuals with low birthweight had a significantly higher risk of diabetes, with an adjusted odds ratio of 3.52 (meaning 3.52 times higher odds) compared to the mid-range birthweight group.
• Insulin resistance (HOMA-IR) was negatively associated with birthweight, meaning lower birthweight was linked to greater insulin resistance, even after accounting for factors like age, sex, current BMI, and family history of diabetes.
• There was no significant association found between birthweight and β-cell function (how well the pancreas produces insulin).

Clinical Significance

This study confirms that low birthweight is an independent risk factor for diabetes and insulin resistance in the Japanese adult population, aligning with observations from Western countries. This highlights the importance of early life factors in long-term metabolic health. While the study suggests an association, longitudinal studies are needed to establish a causal relationship.

Key Points for Patients

If you were born with a low birthweight (under 2.5 kg or about 5.5 pounds), this study suggests you might have a higher risk of developing diabetes and insulin resistance as an adult, even if you are Japanese. This emphasizes that factors from very early in life can impact your health later on. If this applies to you, it may be even more important to maintain a healthy lifestyle, including diet and exercise, and talk to your doctor about monitoring your diabetes risk.

DOI: Read the original article

Effect of peer education on self‐management and psychological status in type 2 diabetes patients with emotional disorders

Authors: Yan Liu, Ying Han, Jieli Shi, Ruixia Li, Sufen Li, Nana Jin, Yong Gu, Honglei Guo

Research Objective

The purpose of this study was to evaluate how peer education affects metabolic indicators and psychological well-being in patients with type 2 diabetes who also experience emotional disorders.

Methods

Researchers identified 127 type 2 diabetes patients with emotional disorders using psychological scales. These participants were divided into two groups: one received usual diabetes education, and the other received usual education plus support from peer leaders for 6 months. At the end of the study, their metabolic health, diabetes knowledge, self-management skills, diabetes-related distress, emotional status (anxiety, depression), and quality of life were compared.

Main Findings

• The peer education group showed significant improvements compared to the usual education group in:
  • Anxiety levels (average score of 49.0 vs 54.0)
  • Depression levels (average score of 51.3 vs 55.8)
  • Diabetes knowledge (average score of 18.8 vs 16.3)
  • Diabetes-related distress (average score of 2.67 vs 3.02)
  • Self-management behaviors (average score of 66.5 vs 62.4)
  • Quality of life (average score of -1.98 vs -2.50)
• However, there was no significant difference in metabolic indicators (like blood glucose or HbA1c levels) between the two groups.

Clinical Significance

This study demonstrates that peer education can be a highly effective model for supporting type 2 diabetes patients who also experience emotional disorders. While it didn't directly improve metabolic markers in this study, the significant improvements in psychological well-being, diabetes knowledge, self-management, and quality of life are crucial for holistic diabetes care. This suggests that peer support can empower patients to better cope with their condition and improve their overall mental health, which is an integral part of managing a chronic illness.

Key Points for Patients

If you have type 2 diabetes and struggle with emotional challenges like anxiety or depression, this study shows that joining a peer education group can be incredibly helpful. Getting support from others who understand your experience can significantly improve your mood, increase your understanding of diabetes, help you manage your condition better, reduce your stress, and boost your overall quality of life. Even if it doesn't immediately change your blood sugar numbers, these benefits are vital for living well with diabetes.

DOI: Read the original article

Stabilization of postprandial blood glucose fluctuations by addition of glucagon like polypeptide‐analog administration to intensive insulin therapy

Authors: Susumu Ogawa, Kazuhiro Nako, Masashi Okamura, Takuya Sakamoto, Sadayoshi Ito

Research Objective

This study aimed to understand how adding liraglutide, a glucagon-like peptide-1 (GLP-1) analog, to intensive insulin therapy could help stabilize blood glucose levels after meals (postprandial blood glucose, PBG) in diabetes patients who experience unstable PBG.

Methods

Twenty diabetes patients who had unstable blood glucose after dinner despite intensive insulin therapy participated. For 16 weeks, their bolus (mealtime) insulin dose was reduced by three units for each meal, and 0.9 mg/day of liraglutide was added to their treatment regimen. The researchers compared mean PBG and the standard deviation (SD), which measures fluctuations, after dinner over 28 days, both before and after the combined therapy.

Main Findings

• Both the average postprandial blood glucose (PBG) after dinner declined significantly (from 12.0 ± 1.0 mmol/L to 10.1 ± 0.9 mmol/L).
• More importantly, the fluctuations in PBG (measured by SD) also significantly decreased (from 5.1 ± 0.7 to 3.5 ± 0.8), indicating more stable blood sugar levels.
• Statistical analysis showed that the combined use of liraglutide was a significant factor in reducing these PBG fluctuations.

Clinical Significance

This study demonstrates that adding liraglutide to intensive insulin therapy, even with a reduced insulin dose, not only helps lower post-meal blood glucose levels but also significantly stabilizes their fluctuations. This stabilization can be crucial for better overall glycemic control, reducing the risk of both high and low blood sugar events, and potentially improving long-term diabetes outcomes.

Key Points for Patients

If you are on intensive insulin therapy for diabetes and find your blood sugar levels fluctuate a lot after meals, particularly after dinner, this study suggests that adding a medication like liraglutide (a GLP-1 analog) might help. Even with a slightly lower insulin dose, this combination therapy can make your blood sugar levels more stable after eating, preventing sharp peaks and valleys. This could lead to more consistent blood sugar control and a better quality of life. Discuss this option with your healthcare provider.

DOI: Read the original article